Latest from Georgetown Lombardi Comprehensive Cancer Center

Patrick M. Forde, MBBCh, discusses the future of immunotherapy in early-stage non–small cell lung cancer.

Chul Kim, MD, MPH, discusses the additions of EGFR inhibitors to the lung cancer armamentarium and how to best select therapy for these patients.

Michael J. Pishvaian, MD, PhD, discusses the impact of immunotherapy in the treatment landscape of hepatocellular carcinoma. 

Stephen V. Liu, MD, discusses ongoing developments in the treatment of patients with ALK-positive NSCLC.

Five leaders in the fight against gastrointestinal cancers from academia, the community, and clinic were honored at the 2018 Luminary Awards. 

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with hepatocellular carcinoma.
 

Stephen Liu, MD, provided an enhanced understanding of oncogenic drivers such as EGFR and ALK in patients with NSCLC, sequencing strategies, and the potential application of immunotherapy in later lines of therapy.

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.